BACKGROUND AND OBJECTIVES Autoantibodies to complement C1q (anti-C1q) are associated with the diagnosis of lupus nephritis. In this study, we compare anti-C1q IgG with another complement autoantibody, anti-C3b IgG, as a biomarker of lupus nephritis and lupus nephritis flare. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Our investigation involved the Ohio SLE Study, a prospective observationa...

background: the aim of the present study was to determine the prevalence and prognosis of cerebrovascular accident(cva) and its subtypes among iranian patients with systemic lupus erythematosus (sle). methods: in a cross-sectional study, medical records of 575 sle patients were reviewed. the patients developing cva in their course of disease were extracted. in these patients, data about demogra...

abstract background: the prognosis of sle is int1uenced by the onset of glomerulonephtitis. clinical ttials in lupus nephritis have demonstrated that cyclophosphamide therapy is the superior regimen in the management oflupus nephritis for preserving renal function. objective: the purpose of this study is to define the outcome of renal function with bolus pu lses of cyclophosphamide and steroid ...

normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background: to determine the prevalence of cryoglobulins in iranian patients with systemic lupus erythematosus (sle) and evaluate the correlation of cryoglobulins with disease activity in these patients. materials and methods: in a cross-sectional study, we investigated 80 consecutive women who fulfilled the 1982 revised c...

conclusions post immunization lv is a rare complication of the bcg vaccine and should be considered by any physician. lupus vulgaris is a paucibacillary form of tb. therefore, acid fast bacilli are not detected in most cases. the pcr is a useful method for confirmation of the diagnosis of lv. introduction lupus vulgaris (lv) is one type of cutaneous tuberculosis (tb) but a rare complication of ...

Proliferative lupus nephritis is a strong predictor of morbidity and mortality in patients with systemic lupus erythematosus. Despite improvements in the management of lupus nephritis, a significant number of the patients do not respond to immunosuppressive therapy and progress to end-stage renal failure. In order to optimise the diagnostic strategy and treatment of patients with proliferative ...

tures and functional outcomes. Lupus 1996; 5: 294-9. 8. MOK CC, LAU CS, CHAN YET, WONG RWS: Acute transverse myelopathy in systemic lupus erythematosus: Clinical presentation, treatment and outcome. J Rheumatol 1998; 25: 467-73. 9. OSAWA H, YAMABE H, KAIZUKA M, et al.: Systemic lupus erythematosus associated with transverse myelitis and parkinsonism symptoms. Lupus 1997; 6: 613-5. 10. BAVILE L,...

common lupus. BMJ 1888; 1:58–63 3 Su WP, Perniciaro C, Rogers RS III, et al. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994; 54:395–399 4 Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus: a review of literature. Clin Rheumatol 2008; 27:1341 5 Richez C, Dumoulin C, Schaeverbeke T. Inf...

INTRODUCTION In systemic lupus erythematosus, acute kidney injury is usually associated with severe lupus nephritis and rarely associated with other glomerular diseases. CASE PRESENTATION We recently encountered a patient with acute kidney injury that was associated with minimal change disease in systemic lupus erythematosus. A 26-year-old Chinese woman who had a history of systemic lupus ery...

ANA: antinuclear antibody BID: twice a day CLE: cutaneous lupus erythematosus DIL: drug-induced lupus SLE: systemic lupus erythematosus INTRODUCTION Cutaneous lupus erythematosus (CLE), defined as isolated cutaneous lesions without significant systemic involvement, has a reported incidence and prevalence of 4.3 and 73.2 per 100,000, respectively. It occurs more commonly among women with a repor...